GSK plc is a biopharma company. The Companyâs segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
äŒæ¥ã³ãŒãGSK
äŒç€ŸåGSK plc
äžå Žæ¥May 22, 1972
æé«çµå¶è²¬ä»»è
ãCEOãWaterhouse (Deborah)
åŸæ¥å¡æ°68629
蚌åžçš®é¡Depository Receipt
æ±ºç®ææ«May 22
æ¬ç€Ÿæåšå°980 Great West Road
éœåžBRENTFORD
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœUnited Kingdom
éµäŸ¿çªå·TW8 9GS
é»è©±çªå·442080475000
ãŠã§ããµã€ãhttps://www.gsk.com/
äŒæ¥ã³ãŒãGSK
äžå Žæ¥May 22, 1972
æé«çµå¶è²¬ä»»è
ãCEOãWaterhouse (Deborah)